for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Ipsen Announces Positive Results From Phase III CheckMate -9ER Trial

April 20 (Reuters) - IPSEN SA:

* POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE III CHECKMATE -9ER TRIAL EVALUATING CABOMETYX® (CABOZANTINIB) IN COMBINATION WITH OPDIVO® (NIVOLUMAB) IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

* STUDY MET PRIMARY ENDPOINT OF SIGNIFICANTLY IMPROVING PROGRESSION-FREE SURVIVAL, SECONDARY ENDPOINTS OF OVERALL SURVIVAL AND OBJECTIVE RESPONSE RATE VERSUS SUNITINIB

* CABOMETYX IN COMBINATION WITH OPDIVO DEMONSTRATES CLINICALLY MEANINGFUL EFFICACY RESULTS ACROSS ALL ENDPOINTS AND PRELIMINARY ASSESSMENT SHOWING A FAVORABLE SAFETY PROFILE

* TRIAL CO-FUNDED BY BRISTOL MYERS SQUIBB, EXELIXIS, IPSEN AND TAKEDA Source text: bit.ly/2KlXzFH Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up